

MULTI-REGIONAL CLINICAL TRIALS

THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD

> Announcing a Global Standard for Plain Language in Clinical Research

Our webinar with **COISC**



Moderated by Barbara E. Bierer, MD MRCT Center, Faculty Director

Disclaimer

- The opinions contained are those of the authors and are not intended to represent the position of Brigham and Women's Hospital or Harvard University.
- The MRCT Center is supported by voluntary contributions from foundations, corporations, international organizations, academic institutions and government entities (see <u>www.MRCTCenter.org</u>), as well as by grants.
- We are committed to autonomy in our research and to transparency in our relationships. The MRCT Center—and its directors—retain responsibility and final control of the content of any products, results, and deliverables.





A joint webinar by the MRCT Center and CDISC April 5, 2023 11 AM - 12 PM EDT

Clinical Research





THE MRCT CENTER of BRIGHAM AND WOMEN'S HOSPITAL and HARVARD




Session Agenda

- Welcome and Introductions MRCT Center and CDISC
- Glossary Background and Development
- Introduction to Public Review
- Q&A

Please note – the recording, slides and bio book will be available by the end of the week



Panelist Introductions



Sylvia Baedorf Kassis, MPH MRCT Center R. Bernard Coley, JD, MBA Advocate

Dave Evans, MS CDISC

Erin Muhlbradt, PHD NCI EVS



The Multi-Regional Clinical Trials Center (MRCT Center)


The MRCT Center is a research and policy center focused on addressing the conduct, oversight, ethics, and regulatory environment of clinical trials.

Our Vision

Improve the integrity, safety, and rigor of global clinical trials.

Our Mission

Engage diverse stakeholders to define emerging issues in global clinical trials and to create and implement ethical, actionable, and practical solutions.







Clinical Research

HARVARD

Longstanding Commitment to Health Literacy

2019 - Multi-stakeholder initiative to launch a publicly available Health Literacy in Clinical Research website

www.mrctcenter.org/health-literacy


2020 - Developed COVID-19 research pamphlets (in English & Spanish). <u>https://mrctcenter.org/blog/resources/covid-19-clinical-research-flyers/</u>

2019 to present - Design and deliver health literacy trainings

2020-2021 - Launched the first pilot version of the Clinical Research Glossary through an agile iterative development process involving many stakeholders, patients, and their allies

https://mrctcenter.org/clinical-research-glossary/

2021 – Robust appreciation and utilization, prompting extensive further development



Introducing CDISC


- CDISC Clinical Data Interchange Standards Consortium
 - Develops and advances data standards of the highest quality to transform incompatible formats, inconsistent methodologies, and diverse perspectives into a robust framework for generating accessible clinical research data.
 - Convenes a global community of research experts representing a range of experiences and backgrounds to harness the collective power to drive more meaningful clinical research.
 - Offers a quarterly public review period for new additions to its standards, a time when feedback can be collected from its users.
- CDISC has always been an evolving transformational standards organization for information used in clinical research and regulatory submission.



CDISC Alliances and Collaborations

CFAST & Therapeutic Area Partnerships

CDISC collaborates with many organizations to develop Therapeutic Area (TA) standards for multiple disease areas through the Coalition for Accelerating Standards and Therapies (CFAST) initiative, as well as other partnerships.



Standards Development Organizations (SDO) Collaborations

CDISC collaborates with other SDOs to develop standards that are synergistic to support a learning health system based upon high quality research.



cdisc

April 5, 2023

CDISC and PhUSE partner to further the mission of each organization collectively, with CDISC focusing on the development of global, platformindependent data standards, and PhUSE focusing on the implementation and use of the CDISC standards. The two organizations work to combine efforts on key initiatives around end-to-end standards, TA standards, and semantics, strengthening an interdependent process.

Regulatory Collaborations

CDISC works closely with regulators around the world to ensure that CDISC

standards will 1) streamline research from protocol/study design and trial

registration through analysis and reporting; 2) facilitate the eSubmission review



CDISC Standards Are Used by US NIH Centers for Many Kinds of Medical Research



Controlled Terminologies in NCI EVS, BRIDG model, Cloud Commons pilot




NINDS CDEs used in Parkinson's and TBI TAs for FDA submissions



Adopted CDISC standards for FDA submissions, HIV studies, pharmacovigilance, and metaanalyses



CDE contributors to Schizophrenia TA, Future CDE alignment to PTS TA





Pediatric terminologies developed with NCI EVS and CDISC



Also in Europe



Vaccines Standard Training on collection, modeling and aggregation standards for interoperability

TRANSFoRm

Mobile patient reported outcomes (PRO)



Standards Starter Pack Curation pipeline to TransMART



Data sharing recommendations



Use of standardized data for research sourced from multiple EHRs



Infectious Diseases - field research data collection and aggregation support




CDISC Membership

<u>A</u> 2	77		ABOND		accenture		O ACI		AT	AdClin!"	ARA	Coloradiana Pasadara	ADVARRA		Aperturnation of	aixial	-		ALEXAN	alimentiv	ALL RINGLAS
	EMORNEROS	AND A	AMGEN		AnalysisMate	argenx	Toma Str.	a Streets	BOCLINCA		ACRO	BIOMARIN	hauteres	ARG	atorus	(basilea)	BATTELLE	Baxter	- there are	Inter Odinan	BeiGese
N.	A	Connect	- mr	-	E	C BRANK		ALIANKASE	CATO SHE	Gilles	Biogen	COAR		bioskin"	BIOSTATA		A. MARINE	-	CHINOOK	(Spreduce	(a) Bostringer Ingeliefen
Windowski ferson	Cittar	CTDS II	CANCER	-		CCS	G castor	av.	Clupea		CODEX.	Cognigen	State in the state of the		CORBUS Y	CERTARA	Contexves	BLUEBALION	COVAREE	Contraction of the	O CinChoke
Contraction of the second	Quin		CT/DMC	CRAB	Capish	CLINEARCH	Carness Mar		cros nt	CROS ALLINCY	Grant Sector	If Children	Cognitive	V	Cutel	Corcept	æ	۲	Entransitiveles	© CPC	EDETEK
Swise >	📜 Дасіма	0	DANONE			22.8	deciphera	Deloitte	DFC	imo"	EORTC			and the	Dimed	СутомХ	00	dsgede	Querente et	Ø «Cinical	Balapager .
Eisal	< faro	Dalkhi-Sarikyo	NUYAICIA		C	FERRING	EMBann.	emergent	7 🔺	a Presidente Series	(BRI)		and and a		ERT	CE L		PARTEST	GLEAD		GI Gandree
Roche	h ² o	Paropertos	Lilly	5	Constant.	HERAX	HMS M				Instate	5	PRED HUTCH		FUĴĨTSU	GEM	DIAL	in the galaxies in	Review of	Similia	Intercept 👔
×	0000	• ICRC-WEITER	11011	4	autin		analytical suffrages	inte		-	\$ <u>\$</u>	(CR	Ginetern	~		(iba	2755	SIPSIN	AIVOIII	D	
40	C and the same	0 2007004	00 ***	Internet 1	jmp	(and the second	ALMEDIS		MAYO		() III	reditata	b .		KINIK	111111111			medrio	Mel	() Meditoria
AMED	III LFB	main	Linkal	MAPS.		maru	Trove	sar	CLINIC	GEO	Myla	Henrie .	Parat and		(instan	8		NAVITAS	NUTRING LINE	pds	4101/000-0
	a Yeller	analytics	MIRATI		· angeneration	mode		Sectors 2	@MOSIN		NRG	V	Number	t t	秦 NORD	C MONATIS	tara	-	PINNÁCLE=	Pfiror	C PARTIES
Providence .	Microsoft	ORACLE	000	OM	ORION		Otsuko	4Pranua	Quadrate	hartan			9 mar	ATL.	Perlo St	REATA	ROKC	1-+	() montant	StPlanalte	0
PREVAIL	MOCULATIO	profil	Progenics	-	1	5	H TRE	Santen	Sas	iAN	R	SCSK	RAREX	-	9	0	SGS			Rho	SEMINS
	Saama	Second Second	SAGE	R	RANFORD	SANOFI	§ same a	TRIALSTAT	TRIALWISE	Q TRINDS	trifecta 🗭	Clevely fair	SENJU	and other a	Seven in One	() here		②時期社	B SHONOGI	2	Syneos
	+ 105 400	Takumi	MIRCK	teva	¢ Emmes	The strategy must	HELMSLEY	gnesser	MRXAR		C. THERMOLE	Benneros.	33	-	SUBC	'TORAY'	ucb	Symbionce	@	8 * M Y O D	MEVEDONE
Veeva	E	Veramed	VERISTAT	VERTEX	ZIFQ	Viitai	P	P	Sound a	Westat	Bosoio	YM	I		CUniWeb	Xact	-	0	-	SOC	uhogenyk Alkermes
Systex	EXTERNED/1	prime	0	Viedoc# +SymBio	🛃 Almirall	grit 🔁	ZOI-ab	Capenity	<u>1000000000000000000000000000000000000</u>		2 Ainylam	Par	Charactery	*	MERCK	in	-	grammer	MENARINI	BOLOODS-	Bildenow
Chinase Stronger	Southilliple	CRC	SON	uni.lu	· Debiteration	IONIS	ŚCT	Signifikans PPD		CRISPR	arix	E.S.C. &	6. 607-	Accord	TGCP-Service	IOHROICO	Mayentra	() cancer		UMIN	CAMINDAS -




12

CDISC Library Provides the Foundation



CDISC Library Provides the Foundation






CDISC Strategy 2023

- Move towards providing all standards in machine-readable and the technology framework for standards metadata implementations
 - to allow for consistent and contextually accurate representations of clinical research information that can be shared efficiently among the community of researchers, companies and regulators
- Expand development of Biomedical Concepts/Trial Design/Protocol Models
- Create a digital data standards framework to accommodate multiple data collection settings and modalities for RWD
- Expand CDISC standards to address the challenges of RWD sources harmonization while maintaining contextual integrity including expanding the reach of standardized Controlled Terminology
- Expand standards development and maintenance to support clinical operations (e.g., Trial Master File RM) and additional Therapeutic Areas



Benefits of Collaboration

- Consistency
- Accuracy
- Reliability
- Transparency
- Trustworthiness





The Clinical Research Glossary - Need and Mission

- Before 2020, a resource of consistent, accurate, and simplified definitions for use across the research industry did not exist.
- Identified a need to develop a unified approach that best supports patients, participants and their caregivers.

Mission to develop a plain language glossary that includes definitions that are:


- > Co-created with patients, participants, and caregivers,
- > Designed for public understanding,
- > Accepted by industry and academic stakeholders across the clinical research ecosystem,

> Facilitating communication around research.



Clinical Research Glossary - Pilot

- Piloted in 2020
- 53 definitions released in 2021
- www.mrctcenter.org/clinical-research-glossary



Baedorf Kassis S, White S, & Bierer B. (2022). <u>Developing a consensus-driven</u>, <u>plain-language clinical research glossary for study</u> <u>participants and the clinical research community</u></u>. *Journal of Clinical and Translational Science*, 1-20. doi:10.1017/cts.2022.12






Current format for each definition:

Randomization

A way to use chance to place study participants into different study treatment groups.

How to say: . Randomization




USE IN A SENTENCE

Researchers use randomization to make sure that study groups are similar and chosen fairly.

MORE INFO

Every participant has a chance to be put into one of the study groups. No one can choose which group a participant is placed in, because it is done by a computer program.

Randomization helps make sure the study groups can be compared against each other at the end of the study. This is a way to avoid bias.



-

- Patients, participants, caregivers, and the public
- People who create research materials for a non-technical audience
- Research sponsors and researchers to use common language




If you know of another resource that could help explain this tem, please contact us!

Clinical Research Glossary Expansion Activities

- Goal of 150 new definitions this year
- Diverse Workgroup
 - Development Team (DT)
 - o 20+ members
 - Multi-stakeholder, including patient/caregiver advocates
 - o CDISC representatives joined in January 2023
 - Review Team (RT)
 - o Small group (~6)
 - All patient/caregiver advocates
- Monthly written feedback and consensus conversations




Clinical Research Glossary – Expansion Process to Date






Clinical Research Glossary – How we Define



- * single sentence definition
- * no complex sentences
- * no long sentences
- * no parentheses, symbols, or abbreviations
- * short, simple words
- * tone that is conversational
- * no words or terms that do not change the message of the sentence
- * active voice whenever possible



Clinical Research Glossary – How we Refine



Clarity – is the content clear?

Accuracy – is the content accurate?

Consistency – is the content consistent with other similar glossary definitions? **Plain language** – is the content in plain language?

Understandability – is the content understandable to patients/participants?

Agreement – does the content agree with other authoritative definitions?

Context – can the content be used across research contexts?

Other – are there any other concerns not noted above?

Can I accept this definition?



Reflections on the MRCT Center Process



What makes this process work

Robust consideration of usage context Respect for lay perspectives Diversity of experienced perspectives




What this process, and collaboration with CDISC, means for patients

Validated definitions Trustworthy and vetted content Bi-Directional knowledge exchange



Clinical Research Glossary – New addition starting March 2023






CDISC Public Review Process

COISC Wiki Spaces ~		Q Search	රුරු 🕐 Log in Sign up							
Controlled Terminology	Pages / Controlled Terminology / Public Review									
(CT)	Terminology Call for Public Review Package P54 - Comments Due by 21 Apr 2023									
SPACE SHORTCUTS	Created by Ann White, last modified by Erin Muhlbradt on Mar 30, 2023									
(File lists	CDISC invites you to submit comments during the Public Review for Controlled Terminology Package 54, which consists of the following 20 documents:									
Q	Controlled_Terminology_Requests_Denied_P54 IS Terminology Mapping Codetable_P54 ODS Naming and Rusinges Pulse									
PAGE TREE	 QRS Naming and Business Rules Rules for Immunogenicity Specimen Tests 									
Guiding Principles	Rules for MB and MS		Reviewers register and							
 Public Review 	Rules for PK ADaM	log into the CDISC WIKI to comment via JIRA								
• Terminology Call for Public Rev	Biospecimens									
 Terminology Teams 	Cell Phenotyping									
	CV* Define-XML									
Change Control Logs	General									
Requests Denied	• Lab*									
> CDISC CT Meeting Minutes	Microbiology-Immunology									
CDISC Controlled Terminology Anr	 MRCT Plain Language Glossary (New!) Oncology 									
SDTMIG and SDS Team Work	• PK									
	Protocol Entities									
File lists	• SEND									
	• UNIT									
	An * indicates that changes or retirements of existing CDISC Submission Values are included on the "Changes to Existing" tab in the document. Please review these changes as there may be submission value changes or term deprecations.									
Space tools	Comments due: 21 Apr 2023									
	Instructions for Reviewers									

https://wiki.cdisc.org/display/CT/Terminology+Call+for+Public+Review+Package+P54+-+Comments+Due+by+21+Apr+2023



3 Steps for Public Review




** If you have difficulty with the JIRA process you can also provide feedback by email

muhlbradtee@mail.nih.gov



JIRA - How to Submit Comments through CDISC JIRA

- Navigate to the CDISC page: <u>https://jira.cdisc.org/secure/Dashbo</u> <u>ard.jspa</u>
 - This will require a login
- Once you are logged into JIRA
 - Click on 'Create' button at the top of the page





Create a JIRA Issue (1 of 2)

Configure Fields Create Issue Select Template All fields marked with an asterisk (*) are required Controlled Terminology (CT) \sim Review Comments × (?) Issue Type* Project (Dropdown) Summary* - Controlled Terminology (CT) Component/s Start typing to get a list of possible matches or press down to select. Issue Type (Dropdown) Package Nonev - Review Comments Fix Version/s None Description _~~ ~~ W = ≣ © - + -Style 🛩 в Τ υ \$ • Summary (*Free Text*) Component/s (Dropdown) -MRCT Package (Dropdown) Text 5 0 Review Period None \sim Review period in which the issue applies to or was created in. Description (*Free Text*) Labels Begin typing to find and create labels or press down to select a suggested label **Review Period** Create another – Public Review Create Cancel **Clinical Research**

- 54


GI OSSA

Create a JIRA Issue (2 of 2)

- Ignore the 'Labels' field
- Click the 'Create' button to generate the JIRA comment
- If you want to create more than one JIRA comment, click the 'Create another' box BEFORE clicking the 'Create' button.

Trouble entering feedback?

 Please contact Dr. Erin Muhlbradt who can submit JIRAs on your behalf: <u>muhlbradtee@mail.nih.gov</u>




Extra Help

HOW TO SUBMIT COMMENTS ON GLOSSARY DEFINITIONS VIA JIRA (VIDEO)

Date: March 30, 2023

Description: Clinical Data Interchange Standards Consortium (CDISC) offers a quarterly public review period, a time when feedback on its new standards can be collected from its users. The plain language definitions developed for the MRCT Center Clinical Research Glossary will be included as a CDISC standard starting in 2023 and will go through a public review process. This helpful video explains how to submit public comments to JIRA, a software application that tracks comments in an organized way.



https://mrctcenter.org/blog/resources/how-to-jira-video/



Clinical Research Glossary – What's Next

- Respond to March/April public review feedback.
- Continue developing definitions and content.
- Prepare for the June public review period.
- Develop a new glossary website with improved search functionality and usability.
- Release the updated MRCT Center Clinical Research Glossary with the CDISC plain language standard at the end of 2023.
- Ongoing considerations for translation into additional languages.





- This collaboration with CDISC offers broadened dissemination and uptake opportunities, and a chance to hear directly from users.
- We will work together to meet the goal of releasing a new website with all our defined words plus all the definitions available as a CDISC standard by the end of 2023.
- New content will continue to be developed and added in 2024 and beyond....
- We encourage you to take part in the Public Review and use the glossary!



Thank you to our Expert Advisory Committee (EAC)

Current Members:

- Annlouise Assaf, Pfizer
- Jay Duhig, Abbvie
- Lori Hall, Legacy Health Strategies
- Julie Holtzople, AstraZeneca
- Barbara Kress, Merck
- Elisabeth Oehrlein, Applied Patient Experience
- Marian Ryan, Institute for Healthcare Advancement
- Karlin Schroeder, Parkinson's Foundation
- Christopher Trudeau, University of Arkansas
- Tianna Umann, Microsoft
- Robert Weker, Patient Advocate

Thank you to the workgroup members who contributed to the pilot

Behtash Bahador Sarah Balay Stephen Carr Jessica Chaikof Lisa Chamberlain James Deborah Collyar Jean-Marc Ferran Helle Gawrylewski Art Gertel Lauren Hamill Shannon Hamill Julie Holtzople

Marilyn Neault Elyssa Ott **Brandis Pickard** Robyn Rennick Marian Ryan T.J. Sharpe Kamila Sroka-Saidi Mary Stober Murray Gloria Stone Michelle Teufel Desiree A.H. Walker **Robert Weker**



Thank you to our current workgroup

Development Team

Behtash Bahador, *CISCRP* Rebecca Baker, CDISC Lisa Chamberlain James, *Trilogy Writing* R Bernard Coley, *Advocate* Deborah Collyar, *PAIR/Advocate* Scott Finger, *CISCRP* Helle Gawrylewski, *Hawkwood Consulting, LLC* Art Gertel, *MedSciCom, LLC* Julia Hild, *Boehringer-Ingelheim* Monica Helton, *Eli Lilly* Maureen Kashuba, *Merck & Co*.

Kevin Kwok, Advocate Rena Lubker, Medical University of South Carolina Keri McDonough, Syneos Alice Miller, Syneos Erin Muhlbradt, NCI Enterprise Vocabulary Services **Marilyn Neault (co-lead), Advocate** Robyn Rennick, GlaxoSmithKline Harold Silverman, argenx Gloria Stone, G Stone Connections Jamie Tyrone, Advocate Cornelia Weiss-Haljiti, Boehringer-Ingelheim

Review Team

Roberta Albany, *Advocate* Jessica Chaikof, *Advocate* Talia Cohavi, *Advocate* Maura Cummings, *Advocate* Anne Marie Mercurio, *Advocate* Kimberly Richardson, *Advocate* TJ Sharpe, *Advocate* **Desiree Walker (co-lead),** *Advocate*



Time for questions



Join us:



and HARVARD



MRCTcenter.org







